


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
CATEGORY I INNOVATIVE MEDICINE “TDI01” OBTAINED APPROVAL
FOR COVID-19 CLINICAL TRIAL

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the category I innovative medicine “TDI01” self-developed by Beijing Tide Pharmaceutical Co. Ltd., a subsidiary of the Company, has been approved by the National Medical Products Administration of China on 23 September 2022 to commence clinical trial for the treatment of Novel Coronavirus Pneumonia (“**COVID-19**”). TDI01 is the world’s first innovative small molecule medicine that inhibits novel coronavirus infection to host cells by highly selective inhibition of ROCK2 kinase, thereby achieving significant anti-viral effect. TDI01 was previously approved for clinical trials in China and the United States for the treatment of idiopathic pulmonary fibrosis and in China for the treatment of pneumoconiosis. COVID-19 is its third indication approved for the clinical trial. The Group will continue to explore the application of TDI01 in more indications.

TDI01 works by inhibiting viral attack and replication through highly selective inhibition of ROCK2 target to achieve anti-viral effects, which is a novel anti-viral mechanism that has shown significant inhibition of novel coronavirus in vitro and in vivo animal experiments, as well as anti-inflammatory and anti-fibrotic effects. TDI01 is a category I small molecule oral medicine for the treatment of COVID-19 with novel mechanism and brand-new target and structure, which differentiates itself from the traditional anti-novel coronavirus medicines currently under development worldwide and in China. TDI01 has now completed the Phase I clinical trial in the United States with a good safety profile and has also completed the human race bridging study of Phase I clinical trial in China.

The approval of TDI01 in the clinical trial for the treatment of COVID-19 brings a potential treatment option with a new mechanism for the global fight against COVID-19. The approval of TDI01 for clinical trials in three major indications in the respiratory field will further increase the Group's product pipeline of innovative drugs in the respiratory field and bring new treatment option to patients with respiratory diseases.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 26 September 2022

As at the date of this announcement, the Board of the Company comprises eight executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.